The VTEU network includes eight university research hospitals and medical organizations across the United States.
According to a statement issued by the National Institute of Allergy and Infectious Diseases, initial studies at the VTEUs were designed to examine novel H1N1 vaccine dosage and protective immune responses in healthy adults (aged 18-64 years old) and elderly people (aged 65 years and older).
The data gathered by the VTEUs "will be factored into the decision about how and if to implement a 2009-H1N1 flu immunization program this fall," Dr.
According to a written statement issued by the NIH, initial studies at the VTEUs were designed to examine whether one or two 15-mcg doses of H1N1 vaccine would be needed to induce a potentially protective immune response in healthy adults (aged 18-64 years old) and elderly people (aged 65 and older).
The other VTEUs are located at Baylor College of Medicine, Houston; Children's Hospital Medical Center, Cincinnati; Emory University, Atlanta; Group Health Cooperative, Seattle; University of Iowa, Iowa City; University of Maryland School of Medicine, Baltimore; and Vanderbilt University, Nashville, Tenn.
The BCM VTEU has worked on numerous vaccines, including those for prevention of influenza, whooping cough, bacterial pneumonia, smallpox, tularemia, anthrax and parasitic microbes.
Now, BCM VTEU investigators are studying candidate pandemic influenza vaccines, pneumococcal vaccines, novel seasonal influenza vaccines, an HIV vaccine and a smallpox vaccine.